Cell Therapeutics Inc., of Seattle, received a patent for a class of small-molecule antitubulin agents with anti-proliferative and tumor-killing activity, including lead compound CT-45099.

DiagnoCure Inc., of Quebec City, was granted U.S. Patent No. 7,008,765, titled "PCA3, PCA3 genes and methods of use," confirming the company's exclusive rights to its prostate-specific gene.